Daily Stock Analysis, CFRX, ContraFect Corp, priceseries

ContraFect Corp. Daily Stock Analysis
Stock Information
Open
1.15
Close
1.20
High
1.20
Low
1.14
Previous Close
1.10
Daily Price Gain
0.09
YTD High
2.50
YTD High Date
Mar 10, 2017
YTD Low
1.10
YTD Low Date
Jun 20, 2017
YTD Price Change
-0.85
YTD Gain
-41.46%
52 Week High
3.28
52 Week High Date
Sep 15, 2016
52 Week Low
1.10
52 Week Low Date
Jun 20, 2017
52 Week Price Change
-1.77
52 Week Gain
-59.60%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 5. 2015
4.33
Mar 17. 2015
4.97
8 Trading Days
14.69%
Link
LONG
Mar 31. 2015
5.15
Apr 16. 2015
5.68
11 Trading Days
10.21%
Link
LONG
Jun 18. 2015
4.75
Jul 1. 2015
5.19
9 Trading Days
9.17%
Link
LONG
Dec 15. 2015
3.89
Dec 30. 2015
4.69
10 Trading Days
20.54%
Link
LONG
May 26. 2016
2.63
Jun 7. 2016
2.91
7 Trading Days
10.59%
Link
LONG
Oct 20. 2016
2.45
Oct 25. 2016
2.58
3 Trading Days
5.31%
Link
LONG
Feb 15. 2017
1.75
Mar 1. 2017
2.10
9 Trading Days
19.74%
Link
Company Information
Stock Symbol
CFRX
Exchange
NasdaqCM
Company URL
http://www.contrafect.com
Company Phone
914-207-2300
CEO
Steven C. Gilman
Headquarters
New York
Business Address
28 WELLS AVENUE, 3RD FLOOR, YONKERS, NY 10701
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001478069
About

ContraFect Corp. is a clinical-stage biotechnology company. It focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases, including those caused by drug-resistant pathogens, particularly those treated in hospital settings. The company scientific and clinical strategy focuses on the use of combination therapies. ContraFect was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.

Description

ContraFect Corporation, a biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies for the treatment of life-threatening seasonal and pandemic varieties of influenza. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.